5:21 PM
 | 
Jan 11, 2018
 |  BC Innovations  |  Translation in Brief

In the twenties

CD27 agonists help myeloid cells chow down on cancer

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing the strategy in the clinic with an anti-CD20 mAb.

Author Sean Lim told BioCentury that while CD27 is primarily known for its co-stimulatory activity on T cells, the target’s therapeutic benefits in this study were mostly due to interactions between mAbs and myeloid cells. “The whole field is focusing on the direct T cell effects of immunostimulatory antibodies, but here, we’ve uncovered a way in which T cell stimulation can benefit direct tumor-targeting antibodies.”

Lim is an associate professor and honorary consultant in hematological oncology at University of Southampton.

“We have been pursuing CD27 combination...

Read the full 633 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >